Abstract
Depression affects a large percentage of the general population and can produce devastating consequences to affected individuals, families and society. Although the treatment of depression has been advanced by traditional antidepressants, improvements are needed across several dimensions (e.g., overall treatment efficacy, therapeutic onset time, and side effect profile). The α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor has an allosteric modulatory site(s) for which potent positive modulators (potentiators) have been designed. These compounds produce antidepressant-like effects in animal models, increase levels of brain-derived neurotrophic factor (BDNF) and engender neurogenesis in vivo. Although these effects are also produced by traditional antidepressants, AMPA receptor potentiators appear to produce their effects through a novel mechanism.
Keywords: ampa receptors, depression, brain-derived neurotrophic factor, bdnf, neurogenesis
Current Pharmaceutical Design
Title: AMPA Receptor Potentiators as Novel Antidepressants
Volume: 11 Issue: 12
Author(s): A. Alt, J. M. Witkin and D. Bleakman
Affiliation:
Keywords: ampa receptors, depression, brain-derived neurotrophic factor, bdnf, neurogenesis
Abstract: Depression affects a large percentage of the general population and can produce devastating consequences to affected individuals, families and society. Although the treatment of depression has been advanced by traditional antidepressants, improvements are needed across several dimensions (e.g., overall treatment efficacy, therapeutic onset time, and side effect profile). The α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor has an allosteric modulatory site(s) for which potent positive modulators (potentiators) have been designed. These compounds produce antidepressant-like effects in animal models, increase levels of brain-derived neurotrophic factor (BDNF) and engender neurogenesis in vivo. Although these effects are also produced by traditional antidepressants, AMPA receptor potentiators appear to produce their effects through a novel mechanism.
Export Options
About this article
Cite this article as:
Alt A., Witkin M. J. and Bleakman D., AMPA Receptor Potentiators as Novel Antidepressants, Current Pharmaceutical Design 2005; 11 (12) . https://dx.doi.org/10.2174/1381612053764814
DOI https://dx.doi.org/10.2174/1381612053764814 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Neuro-Transmitters in the Central Nervous System & their Implication in Learning and Memory Processes
Current Medicinal Chemistry The Identification and Characterization of Excitotoxic Nerve-endings in Alzheimer Disease
Current Alzheimer Research An Agathokakological Tale of Δ<sup>9</sup>-THC: Exploration of Possible Biological Targets
Current Drug Targets TGF-β Signaling in Gastrointestinal Cancer Stem Cells
Current Cancer Therapy Reviews Perinatal Brain Injury
Current Pediatric Reviews Grey Matter Atrophy in Mild Cognitive Impairment / Early Alzheimer Disease Associated with Delusions: A Voxel-Based Morphometry Study
Current Alzheimer Research Levamisole-Induced Leukoencephalopathy in Russia: Analysis of 30 Cases
Current Drug Safety Potassium Channels and CNS Diseases
CNS & Neurological Disorders - Drug Targets Renin-Angiotensin-Aldosterone System: A Current Drug Target for the Management of Neuropathic Pain
Current Drug Targets Cannabinoids and Neuro-Inflammation: Regulation of Brain Immune Response
Recent Patents on CNS Drug Discovery (Discontinued) Hypoxia, Lead Toxicities and Oxidative Stress: Cell Signaling, Molecular Interactions and Antioxidant (Vitamin C) Defense
Current Signal Transduction Therapy Treatment of Viral Encephalitis
Central Nervous System Agents in Medicinal Chemistry Functions of Fukutin, a Gene Responsible for Fukuyama Type Congenital Muscular Dystrophy, in Neuromuscular System and Other Somatic Organs
Central Nervous System Agents in Medicinal Chemistry Interactions Between Apo E and Amyloid Beta and their Relationship to Nutriproteomics and Neurodegeneration
Current Proteomics VEGF Inhibitors and Prostate Cancer Therapy
Current Molecular Pharmacology Single Amino Acid Repeats Connect Viruses to Neurodegeneration
Current Drug Discovery Technologies Drug-Resistance in Central Nervous System Tumors: From the Traditional Cell-Resistance Model to the Genetically Driven Approaches on Therapy
Current Pharmaceutical Biotechnology 5-ht6 Receptors
Current Drug Targets - CNS & Neurological Disorders Genomic and Epigenomic Instability, Fragile Sites, Schizophrenia and Autism
Current Genomics The Response of the Aged Brain to Stroke: Too Much, Too Soon?
Current Neurovascular Research